Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 1, 2009, Pages 85-93

  Galla, John M ^a   Nicholls, Stephen J ^a  

^a Center for Cadiovascular Diagnostics and Preention   (United States)

Author keywords

Atherosclerosis; Cardiovascular prevention; Diabetes; Imaging; Risk factor

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FENOFIBRATE; GLICLAZIDE; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; PIOGLITAZONE; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL;

ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTERY WALL; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; INSULIN TREATMENT; INTRAVASCULAR ULTRASOUND; KIDNEY DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; ABDOMINAL FAT; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CORONARY BLOOD VESSEL; DISEASE COURSE; DRUG EFFECT; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ABDOMINAL FAT; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; OBESITY; RISK FACTORS;

EID: 60549100872     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.1.85     Document Type: Review

References (66)

1. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004).
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504 (1997).
3. Wendt T, Bucciarelli L, Qu W et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr. Atheroscler. Rep. 4, 228-237 (2002).
4. Singer DE, Nathan DM, Anderson KM et al. Association of HbA1c with prevalent cardiovascular disease in the original. cohort of the Framingham Heart Study. Diabetes 41, 202-208 (1992).
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
6. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann. Intern. Med. 147, 578-581 (2007).
7. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298, 1189-1195 (2007).
8. Lipscombe LL, Gomes T, Levesque LE et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298, 2634-2643 (2007).
9. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
10. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008).
11. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N. Engl. J. Med. 357, 28-38 (2007).
12. Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113, 2363-2372 (2006).
13. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med. 353, 2643-2653 (2005).
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
16. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
17. Hanefeld M, Cagatay M, Petrowitsch T et al. Acarbose reduces the risk for myocardial infarction in Type 2 diabetic patients: meta-analysis of seven long-term studies. Eur. Heart J. 25, 10-16 (2004).
18. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 317, 703-713 (1998).
19. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259 (2000).
20. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362, 782-788 (2003).
21. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 1004-1010 (2002).
22. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829-840 (2007).
23. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
24. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
25. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357 (1998).
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
27. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFcaps/Texcaps. AirForce/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998).
28. Sacks FM, Pfeffer MA, Moye LA et al.; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009 (1996).
29. Shepherd J, Cobbe SM, Ford I et al.; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301-1307 (1995).
30. Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117-125 (2008).
31. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004).
32. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
33. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
34. Buse JB, Bigger JT, Byington RP et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am. J. Cardiol. 99, 21i-33i (2007).
35. Stone PH, Muller JE, Hartwell T et al.; the MILIS Study Group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J. Am. Coll. Cardiol. 14, 49-57 (1989).
36. Nisanci Y, Sezer M, Umman B et al. Relationship between pressure-derived collateral blood flow and diabetes mellitus in patients with stable angina pectoris: a study based on coronary pressure measurement. J. Invasive Cardiol. 14, 118-122 (2002).
37. Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357, 905-910 (2001).
38. Brohall G, Oden A, Fagerberg B. Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet. Med. 23, 609-616 (2006).
39. Katakami N, Yamasaki Y, Hayaishi-Okano R et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with Type 2 diabetes. Diabetologia 47, 1906-1913 (2004).
40. Arakawa M, Hirose T. [Glinide(s), sulfonylurea(s)]. Nippon Rinsho 64, 2107-2112 (2006).
41. Oyama T, Saiki A, Endoh K et al. Effect of acarbose, an α-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in Type 2 diabetes mellitus treated by sulfonylurea. J. Atheroscler. Thromb. 15, 154-159 (2008).
42. Hanefeld M, Chiasson JL, Koehler C et al. Acarbose slows progression of intima - media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35, 1073-1078 (2004).
43. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA 296, 2572-2581 (2006).
44. Davidson M, Meyer PM, Haffner S et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with Type 2 diabetes mellitus. Circulation 117, 2123-2130 (2008).
45. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295, 1556-1565 (2006).
46. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
47. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292, 2217-2225 (2004).
48. Sipahi I, Tuzcu EM, Schoenhagen P et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J. Am. Coll. Cardiol. 48, 833-838 (2006).
49. Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297, 499-508 (2007).
50. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300 (2003).
51. Tardif JC, Gregoire J, L'Allier PL et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297, 1675-1682 (2007).
52. Kornowski R, Mintz GS, Abizaid A, Leon MB. Intravascular ultrasound observations of atherosclerotic lesion formation and restenosis in patients with diabetes mellitus. Int. J. Cardiovasc. Intervent. 2, 13-20 (1999).
53. Nicholls SJ, Tuzcu EM, Kalidindi S et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J. Am. Coll. Cardiol. 52, 255-262 (2008).
54. Nigro J, Osman N, Dart AM, Little PJ. Insulin resistance and atherosclerosis. Endocr. Rev. 27, 242-259 (2006).
55. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299, 1561-1573 (2008).
56. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
57. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298, 1180-1188 (2007).
58. Hedblad B, Zambanini A, Nilsson P et al. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with Type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J. Intern. Med. 261, 293-305 (2007).
59. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 24, 930-934 (2004).
60. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
61. Nair A, Kuban BD, Tuzcu EM et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106, 2200-2206 (2002).
62. Nasu K, Tsuchikane E, Katoh O et al. Plaque characterisation by Virtual Histology intravascular ultrasound analysis in patients with Type 2 diabetes. Heart 94, 429-433 (2008).
63. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in Type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371, 1800-1809 (2008).
64. Kawasaki M, Sano K, Okubo M et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J. Am. Coll. Cardiol. 45, 1946-1953 (2005).
65. 2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1172-1182 (2008).
66. Nicholls SJ, Sipahi I, Schoenhagen P et al. Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat. Rev. Drug Discov. 5, 485-492 (2006).